Salud financiera de hoja de balance de Ho Wah Genting Berhad

Salud financiera controles de criterios 5/6

Ho Wah Genting Berhad tiene un patrimonio de accionistas total de MYR88.2M y una deuda total de MYR8.6M, lo que sitúa su ratio deuda-patrimonio en 9.8%. Sus activos y pasivos totales son MYR131.6M y MYR43.3M respectivamente. El BAIT de Ho Wah Genting Berhad es de MYR5.3M, por lo que su ratio de cobertura de intereses es de 3.6. Tiene efectivo e inversiones a corto plazo que ascienden a MYR11.7M.

Información clave

9.8%

Ratio deuda-patrimonio

RM8.63m

Deuda

Ratio de cobertura de intereses	3.6x
Efectivo	RM11.67m
Patrimonio	RM88.21m
Total pasivo	RM43.35m
Activos totales	RM131.56m

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That Ho Wah Genting Berhad (KLSE:HWGB) Is Using Debt Reasonably Well

May 22

Ho Wah Genting Berhad (KLSE:HWGB) Has A Somewhat Strained Balance Sheet

Dec 06

Here's Why Ho Wah Genting Berhad (KLSE:HWGB) Can Afford Some Debt

Jul 08

Recent updates

Ho Wah Genting Berhad (KLSE:HWGB) Is Experiencing Growth In Returns On Capital

Oct 26

Many Still Looking Away From Ho Wah Genting Berhad (KLSE:HWGB)

Jul 17

These 4 Measures Indicate That Ho Wah Genting Berhad (KLSE:HWGB) Is Using Debt Reasonably Well

May 22

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (MYR90.4M) de HWGB superan a sus pasivos a corto plazo (MYR30.6M).

Pasivo a largo plazo: Los activos a corto plazo de HWGB (MYR90.4M) superan a sus pasivos a largo plazo (MYR12.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: HWGB tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de HWGB ha pasado de 83.9% a 9.8% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de HWGB es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Los pagos de intereses de la deuda de HWGB están bien cubiertos por el BAIT (3.6x cobertura).

Salud financiera de hoja de balance de Ho Wah Genting Berhad

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That Ho Wah Genting Berhad (KLSE:HWGB) Is Using Debt Reasonably Well

Ho Wah Genting Berhad (KLSE:HWGB) Has A Somewhat Strained Balance Sheet

Here's Why Ho Wah Genting Berhad (KLSE:HWGB) Can Afford Some Debt

Recent updates

Full year 2023 earnings released: EPS: RM0.007 (vs RM0.01 loss in FY 2022)

New major risk - Market cap size

New minor risk - Financial data availability

Ho Wah Genting Berhad (KLSE:HWGB) Is Experiencing Growth In Returns On Capital

New major risk - Market cap size

New minor risk - Shareholder dilution

Many Still Looking Away From Ho Wah Genting Berhad (KLSE:HWGB)

These 4 Measures Indicate That Ho Wah Genting Berhad (KLSE:HWGB) Is Using Debt Reasonably Well

Full year 2022 earnings released: RM0.003 loss per share (vs RM0.009 loss in FY 2021)

Second quarter 2023 earnings released: EPS: RM0.002 (vs RM0.007 loss in 2Q 2022)

Ho Wah Genting Berhad (KLSE:HWGB) Has A Somewhat Strained Balance Sheet

Returns Are Gaining Momentum At Ho Wah Genting Berhad (KLSE:HWGB)

Full year 2022 earnings released: RM0.009 loss per share (vs RM0.046 loss in FY 2021)

Ho Wah Genting Berhad, Annual General Meeting, Sep 28, 2022

Ho Wah Genting Berhad has completed a Follow-on Equity Offering in the amount of MYR 2.939792 million.

Here's Why Ho Wah Genting Berhad (KLSE:HWGB) Can Afford Some Debt

Ho Wah Genting Berhad Announces Appointment of Khalid Bin Ahmad Husni as Independent and Non Executive Member of Nomination and Remuneration Committee

Full year 2022 earnings released: RM0.009 loss per share (vs RM0.046 loss in FY 2021)

Ho Wah Genting Berhad Update on Phase 4 United States Food and Drug Administration Clinical Trial of Sars-Cov-2 Vaccine Study

Ho Wah Genting Berhad Appoints Kay Wong-Alafriz, as Advisor

New 90-day low: RM0.55

Full year 2020 earnings released: RM0.044 loss per share (vs RM0.019 loss in FY 2019)

Ho Wah Genting Berhad Appoints Law Phooi Wong as Advisor to the Board

Ho Wah Genting Berhad Announces Update on Phase 4 Clinical Trial of Sars-Cov-2 Vaccine Study

Ho Wah Genting Berhad Receives Product Registration Approval for Astramern Astra H Capsule from NPRA for A Period Commencing 14 January 2021 to 14 January 2026

Ho Wah Genting Berhad Enters into Memorandum of Understanding with Chongqing ISIA Bio-Technology Co., Ltd (ISIA) to Manufacture and Produce in Vitro Diagnostic Products

New 90-day low: RM0.59

Ho Wah Genting Berhad Provides Update on Phase 4 Clinical Trial of Sars-Cov-2 Vaccine Study

Ho Wah Genting Berhad Announces Benjamin Leong Wye Hoong as Independent and Non Executive Director

New 90-day high: RM0.89

Ho Wah Genting Berhad Provides Update on the Joint Venture Project with E-Mo Biology Inc

Third quarter 2020 earnings released: RM0.002 loss per share

Ho Wah Genting Berhad Enters into Memorandum of Understanding with GNOSIS LABORATORIES (M) SDN BHD

Ho Wah Genting Berhad Provides Update on the Joint Venture Project with E-Mo Biology Inc

Ho Wah Genting Berhad Announces Appointment as the Authorized Sale Agent/ Distributor for the Covid-19 related products from Wuhan Easy Diagnosis Biomedicine Co.,Ltd

Ho Wah Genting Berhad Announces Resignation of Mr. Bernard Lim Soon Chiang as Independent and Non Executive Member of Remuneration Committee

Ho Wah Genting Berhad Announces Redesignation of Mr. Kenny Yeoh Khi Khen from Independent and Non Executive Member of Risk Committee to Chairman of Risk Committee

First half earnings released

Dato Lim Ooi Hong, Lim Wee Kiat and Datuk Teo Tiew, Executive Directors of Ho Wah Genting Berhad completed the acquisition of remaining 70.24% stake in Ho Wah Genting Berhad (KLSE:HWGB).

New 90-day high - RM0.60

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera